Clinical trial for Renal Cell Carcinoma (Kidney Cancer)
Official title QLESP Block for Pain Control in Robotic Partial Nephrectomy
ClinicalTrials.gov ID: NCT07704970
What this study is testing
What is ropivacaine (local infiltration)?
ropivacaine (local infiltration) is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for renal cell carcinoma (kidney cancer).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to learn if an ultrasound-guided nerve block called QLESP works to reduce pain and the need for strong pain medicines after robotic kidney surgery in adults. The main questions it aims to answer are: 1.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Aged 18 to 75 years
- Scheduled for elective robot-assisted partial nephrectomy (RAPN)
- American Society of Anesthesiologists (ASA) physical status I to III
- Body mass index (BMI) 18 to 35 kg/m²
- Voluntarily signed informed consent form Able to understand pain scoring and use of patient-controlled analgesia (PCA)
You likely can't join if
- Language, communication, or comprehension barriers
- Infection at the intended puncture site
- Coagulopathy or bleeding diathesis
- Known allergy or contraindication to local anesthetics or opioids
- Use of analgesic medications within the past 3 months
- Peripheral neuropathy
See the full eligibility criteria
- Aged 18 to 75 years
- Scheduled for elective robot-assisted partial nephrectomy (RAPN)
- American Society of Anesthesiologists (ASA) physical status I to III
- Body mass index (BMI) 18 to 35 kg/m²
- Voluntarily signed informed consent form Able to understand pain scoring and use of patient-controlled analgesia (PCA)
- Language, communication, or comprehension barriers
- Infection at the intended puncture site
- Coagulopathy or bleeding diathesis
- Known allergy or contraindication to local anesthetics or opioids
- Use of analgesic medications within the past 3 months
- Peripheral neuropathy
- Severe cardiac, hepatic, or renal dysfunction
- Pregnancy or breastfeeding
- Refusal to participate in the study
The study team makes the final eligibility decision.
Where it's taking place
- Wuhan, Hubei, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Wuhan, Hubei, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.